Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

4:31 PM ET 8-K
Financial Results Prairie Operating Co. PROP

Prairie Operating Financial Results

Prairie Operating Co. reported its Q3 2026 financial results, highlighted by a 31% sequential revenue increase to $129.5 million and a 21% increase in sales volumes to 26,117 Boe/d. Despite the revenue growth, the company recorded a net loss of $34.0 million while generating $65.3 million in Adjusted EBITDA.

Term
Q3 2026

“Prairie’s third-quarter results demonstrate the strength of our assets and the excellent work our team continues to deliver across our development program. Average daily sales volumes increased 21% from the prior quarter to 2.4 MMboe or 26,117 Boe per day, driving revenue growth of 31% from the prior quarter to $129.5 million. We achieved that growth while reducing lease operating expense per Boe by 17% from the prior quarter, reflecting our continued focus on improving well performance and operating efficiency.”

Greg Patton, Chief Executive Officer

“Prairie generated $65.3 million of Adjusted EBITDA in the third quarter, an increase of 92% from the prior quarter, as sales volumes increased and unit operating costs declined. With Burnett and Castor now producing, our focus is on realizing the cash returns from the capital invested this year and carefully managing the spending required to sustain that production.”

Michael Shelly, Executive Vice President and Chief Financial Officer
4:31 PM ET 10-Q
Financial Results BlossomHill Therapeutics, Inc. BLSM

BlossomHill Therapeutics Q3 2026 Results: Net Loss of $24M, Loss Widens

BlossomHill Therapeutics is a clinical-stage biopharmaceutical company with two product candidates, BH-30643 and BH-30236, in early clinical development and one preclinical candidate, BH-501284. The company has incurred substantial losses since inception and anticipates continued losses as it advances its precision medicine programs for genetically defined cancers.

Key figure
Net loss $24M
4:31 PM ET Form 4
Insider Selling Addus HomeCare Corp ADUS

Addus HomeCare EVP, Chief Development Officer Cliff Donald Blessing Sells $429K of Stock

Cliff Donald Blessing, EVP, Chief Development Officer, sold 3,464 shares of Addus HomeCare Corp at $123.10 to $124.18 a share (average $123.90) in 2 transactions, worth $429K in total on Nov 10, 2026. Shares held after the trade: 6,719 (-27.7%).

Value
$429K
Shares
3,464
Average price
$123.90
Role
EVP, Chief Development Officer
Holding change
-27.7%
Trade date
Nov 10, 2026
4:31 PM ET Form 4
Insider Buying General American Investors Co Inc GAM

General American Investors Co VP Administration Eugene S. Stark Buys $21.9K of Stock

Eugene S. Stark, VP Administration, bought 1,000 shares of General American Investors Co Inc at $21.95 a share, worth $21.9K in total on Nov 12, 2026. Shares held after the trade: 40,000 (+2.6%).

Value
$21.9K
Shares
1,000
Price
$21.95
Role
VP Administration
Holding change
+2.6%
Trade date
Nov 12, 2026
4:31 PM ET 8-K
Financial Results Legacy Education Inc. LGCY

Legacy Education Financial Results

Legacy Education Inc. reported financial results for its fiscal first quarter ended September 30, 2026, featuring record student population growth of 5.4% year-over-year to 3,684 students. The company achieved revenue of $20.0 million and net income of $0.9 million while expanding its footprint with a new lease for its first planned campus outside California in Houston, Texas.

Term
Q1 2027
4:31 PM ET Form 4
Insider Selling Mgp Ingredients Inc CASK

Sempreon 10% Owner Caroline Lux Kaplan Sells $1.08M of Stock

Caroline Lux Kaplan, 10% Owner, sold 60,000 shares of Sempreon, Inc at $17.63 to $18.26 a share (average $17.94) in 2 transactions, worth $1.08M in total between Nov 10, 2026 and Nov 11, 2026. Shares held after the trade: 410,958 (-6.8%).

Value
$1.08M
Shares
60,000
Average price
$17.94
Role
10% Owner
Holding change
-6.8%
Trade date
Nov 10, 2026 to Nov 11, 2026
4:31 PM ET 8-K
Dividend National Bankshares Inc NKSH

National Bankshares Dividend

National Bankshares, Inc. declared a semi-annual cash dividend of $0.78 per share. The dividend is payable on December 1, 2026, to stockholders of record as of the close of business on November 23, 2026.

Term
semi-annual
4:31 PM ET 10-Q
Financial Results Legence Corp. LGN

Legence Q3 2026 Results: Turns Profitable, Net Income $89.6M

Legence Corp. reported significant growth in total assets to $3.83 billion as of September 30, 2026, up from $2.68 billion at year-end 2025, driven by increases in contract assets and intangible assets. The company maintained a dual-class share structure with 108,527,517 total shares outstanding and reported a reduction in its accumulated deficit from $309.9 million to $232.1 million during the period.

Key figure
Net income $89.6M
4:31 PM ET Form 4
Insider Buying Stevanato Group S.p.A. STVN

Stevanato Group S.p.A Director William J. Federici Buys $274K of Stock

William J. Federici, Director, bought 20,000 shares of Stevanato Group S.p.A. at $13.72 a share, worth $274K in total on Nov 9, 2026. Shares held after the trade: 46,991 (+74.1%).

Value
$274K
Shares
20,000
Price
$13.72
Role
Director
Holding change
+74.1%
Trade date
Nov 9, 2026
4:31 PM ET Form 4
Insider Buying Keenova Therapeutics plc

Keenova Therapeutics Insider Goldentree Asset Management LP Buys $13.7M of Stock

Goldentree Asset Management LP bought 150,652 shares of Keenova Therapeutics plc at $89.25 to $91.00 a share (average $90.65) in 2 transactions, worth $13.7M in total between Nov 9, 2026 and Nov 10, 2026. Shares held after the trade: 9,026,195 (+1.4%).

Value
$13.7M
Shares
150,652
Average price
$90.65
Holding change
+1.4%
Trade date
Nov 9, 2026 to Nov 10, 2026
4:31 PM ET Form 4
Insider Selling Consensus Cloud Solutions, Inc. CCSI

Consensus Cloud Solutions Director Nathaniel Simmons Sells $342K of Stock

Nathaniel Simmons, Director, sold 8,000 shares of Consensus Cloud Solutions, Inc. at $42.46 to $42.90 a share (average $42.78) in 2 transactions, worth $342K in total on Nov 9, 2026. Shares held after the trade: 23,658 (-19.6%).

Value
$342K
Shares
8,000
Average price
$42.78
Role
Director
Holding change
-19.6%
Trade date
Nov 9, 2026
4:31 PM ET Form 4
Insider Buying LEE ENTERPRISES, Inc LEE

LEE ENTERPRISES Director David Henry Hoffmann Buys $99.3K of Stock

David Henry Hoffmann, Director, bought 14,056 shares of LEE ENTERPRISES, Inc at $6.96 to $7.17 a share (average $7.07) in 2 transactions, worth $99.3K in total between Nov 10, 2026 and Nov 11, 2026. Shares held after the trade: 11,544,637 (+0.1%).

Value
$99.3K
Shares
14,056
Average price
$7.07
Role
Director
Holding change
+0.1%
Trade date
Nov 10, 2026 to Nov 11, 2026
4:31 PM ET Form 4
Insider Buying Claritev Corp CTEV

Claritev Insider Ares Management LLC Buys $2.94M of Stock

Ares Management LLC bought 115,579 shares of Claritev Corp at $24.42 to $26.14 a share (average $25.40) in 2 transactions, worth $2.94M in total between Nov 9, 2026 and Nov 10, 2026. Shares held after the trade: 2,049,518 (+3.3%).

Value
$2.94M
Shares
115,579
Average price
$25.40
Holding change
+3.3%
Trade date
Nov 9, 2026 to Nov 10, 2026
4:30 PM ET Form 4
Insider Selling Intercontinental Exchange, Inc. ICE

Intercontinental Exchange General Counsel Andrew J. Surdykowski Sells $801K of Stock

Andrew J. Surdykowski, General Counsel, sold 4,575 shares of Intercontinental Exchange, Inc. at $174.04 to $176.22 a share (average $175.05) in 3 transactions, worth $801K in total on Nov 10, 2026. Shares held after the trade: 40,554 (-1.4%).

Value
$801K
Shares
4,575
Average price
$175.05
Role
General Counsel
Holding change
-1.4%
Trade date
Nov 10, 2026
4:29 PM ET Form 4
Insider Selling CareDx, Inc. CDNA

CareDx Secretary and General Counsel Jeffrey Adam Novack Sells $332K of Stock

Jeffrey Adam Novack, Secretary and General Counsel, sold 4,096 shares of CareDx, Inc. at $80.47 to $83.33 a share (average $81.13) in 3 transactions, worth $332K in total on Nov 10, 2026. Shares held after the trade: 96,604 (-0.9%).

Value
$332K
Shares
4,096
Average price
$81.13
Role
Secretary and General Counsel
Holding change
-0.9%
Trade date
Nov 10, 2026
4:29 PM ET 10-Q
Financial Results Audax Private Credit Fund, LLC

Audax Private Credit Fund Q3 2026 Results: Net Income $18.1M, Up 144.5% YoY

Audax Private Credit Fund, LLC reported a net increase in net assets from operations of $25.6 million for the nine months ended September 30, 2026, compared to $15.2 million in the prior year period. Total investments at fair value grew to $1.21 billion, while the fund maintained a net asset value per share of $24.86.

Key figure
Net income $18.1M · +144.5% YoY
4:29 PM ET 10-Q
Financial Results KBS Real Estate Investment Trust III, Inc. KBSR

KBS Real Estate Investment Trust III Q3 2026 Results: Net Loss of $85.6M, Loss Widens

KBS Real Estate Investment Trust III, Inc. reported a net loss of $137.1 million for the nine months ended September 30, 2026, compared to a $59.9 million loss in the prior year period. The increased loss was driven by $80.0 million in real estate impairment charges and a $19.2 million unrealized loss on real estate equity securities.

Key figure
Net loss $85.6M
4:29 PM ET Form 4
Insider Buying Solaris Energy Infrastructure, Inc. SEI

Solaris Energy Infrastructure Insider Aj Teague Buys $30.8K of Stock

Aj Teague bought 520 shares of Solaris Energy Infrastructure, Inc. at $59.23 to $59.50 a share (average $59.32) in 2 transactions, worth $30.8K in total between Nov 9, 2026 and Nov 10, 2026. Shares held after the trade: 117,385 (+0.1%).

Value
$30.8K
Shares
520
Average price
$59.32
Holding change
+0.1%
Trade date
Nov 9, 2026 to Nov 10, 2026
4:29 PM ET Form 4
Insider Selling Toast, Inc. TOST

Toast Insider Susan Chapman-Hughes Sells $235K of Stock

Susan Chapman-Hughes sold 6,885 shares of Toast, Inc. at $34.13 a share, worth $235K in total on Nov 11, 2026. Shares held after the trade: 7,645 (-47.4%).

Value
$235K
Shares
6,885
Price
$34.13
Holding change
-47.4%
Trade date
Nov 11, 2026
4:28 PM ET 8-K
Financial Results Planet 13 Holdings Inc. PLNH

Planet 13 Holdings Financial Results

Planet 13 Holdings reported Q3 2026 revenue of $23.1 million, a 1.0% sequential increase driven by strong growth in Florida. The company significantly reduced its net loss to $6.4 million compared to $44.0 million in the prior year, aided by improved gross margins and the exit from California operations. Management highlighted the upcoming December 10 shareholder vote on its proposed merger with Vireo Growth.

Term
Q3 2026

“Revenue increased for the second consecutive quarter, up 1.0% sequentially, led by a 15.1% quarter-over-quarter increase in Florida, where revenue was 45% higher than in the prior-year quarter. The levers we have been pulling in Florida are showing up in the numbers driven by better flower out of our upgraded cultivation, a fuller product lineup with BHO concentrates now on shelf, and a more productive store network.”

Larry Scheffler, Co-CEO of Planet 13

“We delivered a second consecutive quarter of revenue growth and Adjusted EBITDA improvement, and our focus remains on running the business well and executing a smooth path to closing for our stockholders, employees, patients and customers. With the Form S-4 declared effective on November 2, our stockholders will vote on the proposed merger with Vireo Growth at a special meeting on December 10, 2026.”

Bob Groesbeck, Co-CEO of Planet 13
4:28 PM ET 8-K
Financial Results Verrica Pharmaceuticals Inc. VRCA

Verrica Pharmaceuticals Financial Results

Verrica Pharmaceuticals reported record Q3 2026 YCANTH net product revenue of $5.7 million, a 57.9% increase year-over-year, and total revenue of $6.9 million. The company completed enrollment in its first Phase 3 pivotal trial for common warts and unlocked $27.5 million in non-dilutive growth capital by meeting credit facility milestones.

Term
Q3 2026

“Verrica made progress in growing our commercial YCANTH business for molluscum contagiosum while advancing our late-stage pipeline for two of the most prevalent skin diseases, and extending our cash runway during the third quarter.”

Jayson Rieger, PhD, MBA, President and Chief Executive Officer

“Under our current operating plan, including finishing the global Phase 3 program in common warts, and the full utilization of our credit facility, we now have sufficient liquidity to fund operations through data readouts for both pivotal trials of the common warts program.”

Jayson Rieger, PhD, MBA, President and Chief Executive Officer
4:28 PM ET 8-K
Loan & Debt Meta Platforms, Inc. META

Meta Platforms Debt Financing Update with Citigroup Global Markets Limited

Meta Platforms, Inc. completed a multi-tranche offering of Senior Notes denominated in Euros across six different maturities ranging from 2031 to 2065. The offering includes €1.75B of 4.300% notes due 2031, €1.25B of 4.650% notes due 2033, €1.00B of 4.900% notes due 2035, €1.75B of 5.400% notes due 2038, €1.75B of 6.050% notes due 2044, and €1.50B of 6.400% notes due 2065. The notes were issued under a seventh supplemental indenture with U.S. Bank Trust Company as trustee.

Counterparty
Citigroup Global Markets Limited and Morgan Stanley & Co. International plc
Term
through 2065
4:28 PM ET 10-Q
Financial Results Robinhood Ventures Fund II RVII

Robinhood Ventures Fund II Q2 2026 Results: Net Loss of $1.88M

Robinhood Ventures Fund II reported a net investment loss of $1.87 million for the six months ended September 30, 2026, with total assets growing significantly to $217.1 million following its IPO in August 2026. The fund's net asset value per share decreased from $24.72 to $23.21 during the period, primarily driven by organizational expenses and offering costs.

Key figure
Net loss $1.88M
4:28 PM ET Form 4
Insider Selling Tim S.A. TIMB

Tim VP, Risk & Compliance Claudio Creo Sells $18.9K of Stock

Claudio Creo, VP, Risk & Compliance, sold 5,000 shares of Tim S.A. at $3.77 a share, worth $18.9K in total on Nov 10, 2026. Shares held after the trade: 21,798 (+29.8%).

Value
$18.9K
Shares
5,000
Price
$3.77
Role
VP, Risk & Compliance
Holding change
+29.8%
Trade date
Nov 10, 2026
4:28 PM ET Form 4
Insider Buying Orchestra BioMed Holdings, Inc. OBIO

Orchestra BioMed Holdings 10% Owner Rtw Investments LP Buys $6M of Stock

Rtw Investments LP, 10% Owner, bought 1,200,000 shares of Orchestra BioMed Holdings, Inc. at $5.00 a share, worth $6M in total on Nov 9, 2026. Shares held after the trade: 10,756,063 (+12.6%).

Value
$6M
Shares
1,200,000
Price
$5.00
Role
10% Owner
Holding change
+12.6%
Trade date
Nov 9, 2026
4:27 PM ET 10-Q
Financial Results Ondas Inc. ONDS ▶ Call

Ondas Q3 2026 Results: Net Loss of $64.7M, Loss Widens

Ondas Inc. reported a significant revenue increase to $301.4 million for the nine months ended September 30, 2026, compared to $20.6 million in the prior year, primarily driven by acquisition activity. Despite a quarterly net loss of $64.7 million, the company achieved a net income of $206.9 million for the nine-month period, largely due to $583.4 million in other income.

Key figure
Net loss $64.7M
4:27 PM ET 8-K
Capital Raise Candel Therapeutics, Inc. CADL

Candel Therapeutics Capital Raise

Candel Therapeutics entered into a Second Amended and Restated Open Market Sale Agreement with Jefferies LLC to establish a new at-the-market (ATM) equity facility. The agreement allows the company to sell up to $50 million of common stock from time to time, in addition to the $50 million previously sold under a prior 2025 agreement.

Counterparty
Jefferies LLC
4:27 PM ET 10-Q
Financial Results Armata Pharmaceuticals, Inc. ARMP

Armata Pharmaceuticals Q3 2026 Results: Turns Profitable, Net Income $54.9M

Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on bacteriophage-based therapies. As of November 6, 2026, the company had 37,192,632 shares of common stock outstanding and is classified as a non-accelerated filer and smaller reporting company.

Key figure
Net income $54.9M
4:27 PM ET 10-Q
Financial Results Xos, Inc. XOS

Xos Q3 2026 Results: Net Loss of $7.61M

For the nine months ended September 30, 2026, Xos, Inc. reported revenues of $21.5 million, a significant decrease from $40.8 million in the prior year period. The company incurred a net loss of $19.4 million for the first nine months of 2026, while its cash position decreased to $12.1 million as of September 30, 2026.

Key figure
Net loss $7.61M
4:27 PM ET 10-Q
Financial Results Newsmax Inc. NMAX ▶ Call

Newsmax Q3 2026 Results: Turns Profitable, Net Income $15.2M

Newsmax Inc. reported a significant financial turnaround for the nine months ended September 30, 2026, achieving a net income of $15.9 million compared to a net loss of $96.5 million in the prior year period. This improvement was driven by a 27.6% increase in total revenues to $174.8 million and a substantial reduction in general and administrative expenses, which had been inflated in 2025 by one-time corporate matters.

Key figure
Net income $15.2M

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.